In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 Feb. 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra
Related stories
Notes from the IAPP Canada: Privacy watchdogs — What the 2024–25 annual reports reveal
A view from DC: Competing Republican visions for tech policy in the 118th Congress
A view from Brussels: Addressing data retention discrepancies
Notes from the Asia-Pacific region: Privacy matters to customers, individuals, society
European Commission receives final version of General-Purpose AI Code of Practice
This article is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.